These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1354024)

  • 1. Intrinsic activity of DA agonists.
    Lahti RA; Figur LM; Piercey MF; Ruppel PL; Evans DL
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():182A-183A. PubMed ID: 1354024
    [No Abstract]   [Full Text] [Related]  

  • 2. Partial brain dopamine D2 receptor agonists in the treatment of schizophrenia.
    Coward D; Dixon K; Enz A; Shearman G; Urwyler S; White T; Karobath M
    Psychopharmacol Bull; 1989; 25(3):393-7. PubMed ID: 2576320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dopanergic agonists and schizophrenia].
    Pidgeon JF; Wolf MA
    Psychiatr J Univ Ott; 1989 Nov; 14(4):529-35. PubMed ID: 2573101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiology and pharmacology of dopamine D2-receptors: their implications in dopamine-substitute therapy for Parkinson's disease.
    Mercuri NB; Calabresi P; Bernardi G
    Neurology; 1989 Aug; 39(8):1106-8. PubMed ID: 2569697
    [No Abstract]   [Full Text] [Related]  

  • 5. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms.
    Wetzel H; Hillert A; Gründer G; Benkert O
    Am J Psychiatry; 1994 Oct; 151(10):1499-502. PubMed ID: 7916543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated stimulation of dopamine D1 receptors enhances the effects of dopamine receptor agonists.
    White FJ; Hu XT; Brooderson RJ
    Eur J Pharmacol; 1990 Dec; 191(3):497-9. PubMed ID: 1982272
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacological bases for the use of dopamine and related drugs in the treatment of congestive heart failure.
    Goldberg LI
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S21-8. PubMed ID: 2483439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of dopamine receptor agonists.
    Murphy MB
    Proc West Pharmacol Soc; 1990; 33():31-5. PubMed ID: 1980363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo assessment of dopaminergic variables in schizophrenia.
    Martinot JL; Paillere-Martinot ML; Lecrubier Y; Dao-Castellana MH; Loc'h C; Poirier MF; Allilaire JF; Feline A; Manus A; Aubin F
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():470A-471A. PubMed ID: 1354053
    [No Abstract]   [Full Text] [Related]  

  • 10. Unilateral inactivation of dopamine receptors after intrastriatal injection of N-ethoxy-carbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): a novel rotational model to investigate dopamine receptor interactions.
    Giorgi O; Biggio G
    Pharmacol Biochem Behav; 1990 Apr; 35(4):877-84. PubMed ID: 1971721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schizophrenia: D4 receptor elevation. What does it mean?
    Seeman MV
    J Psychiatry Neurosci; 1994 May; 19(3):171-6. PubMed ID: 7913338
    [No Abstract]   [Full Text] [Related]  

  • 12. Collaborated basic bio-medical research.
    Farooq S
    J Coll Physicians Surg Pak; 2006 Aug; 16(8):499-500. PubMed ID: 16899174
    [No Abstract]   [Full Text] [Related]  

  • 13. [Dopaminergic receptor activity and the evolution of schizophrenia].
    Fodoreanu L
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1985; 30(2):131-4. PubMed ID: 2864729
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis.
    Imperato A; Di Chiara G
    Eur J Pharmacol; 1988 Nov; 156(3):385-93. PubMed ID: 2905668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroleptics, dopamine, and schizophrenia.
    Pickar D
    Psychiatr Clin North Am; 1986 Mar; 9(1):35-48. PubMed ID: 2870480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological profile of the dopamine (DA) agonists, RS-12254.
    Rosenkranz RP; Caroon JM; Clark RD; Eglen RM; Fisher LE; McClelland DL; Michel AD; Muchowski JM; Whiting RL
    Proc West Pharmacol Soc; 1991; 34():131-4. PubMed ID: 1686321
    [No Abstract]   [Full Text] [Related]  

  • 17. Antagonism of quinpirole by (+)-AJ 76: possible involvement of D3 receptors.
    Gui-Hua C; Woolverton WL
    Eur J Pharmacol; 1991 Dec; 209(3):285-6. PubMed ID: 1686769
    [No Abstract]   [Full Text] [Related]  

  • 18. Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?
    Dépatie L; Lal S
    J Psychiatry Neurosci; 2001 May; 26(3):203-20. PubMed ID: 11394190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pressure-induced disorders in neurotransmission and spontaneous behavior in rats: an animal model of psychosis.
    Abraini JH; Ansseau M; Fechtali T
    Biol Psychiatry; 1993 Nov; 34(9):622-9. PubMed ID: 7904834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotensin attenuates dopamine D2 agonist quinpirole-induced inhibition of midbrain dopamine neurons.
    Shi WS; Bunney BS
    Neuropharmacology; 1990 Nov; 29(11):1095-7. PubMed ID: 1982340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.